Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | SI | P14410 | 3/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987897 | 0.77 | ALDH1A1 (0.38) | MGAMGAASIMGAM2PDE3B | |
| SCHEMBL3656718 | 0.72 | PARP1 (0.40) | L3MBTL1MGAMGAASIMGAM2 | |
| SCHEMBL2133770 | 0.69 | AR (0.44) | DRD4DRD3L3MBTL1MGAMGAA | |
| SCHEMBL3654190 | 0.69 | RAB9A (0.39) | PDE3BPDE3AATMCYP2A6TP53 | |
| SCHEMBL16354262 | 0.69 | XPO1 (0.39) | L3MBTL1MGAMGAASIMGAM2 | |
| SCHEMBL3658725 | 0.68 | GAA (0.39) | GAAPDE3BPDE3ACYP2A6TP53 | |
| SCHEMBL9732163 | 0.68 | DRD4 (0.53) | DRD4DRD3L3MBTL1GAAPDE3B | |
| SCHEMBL466391 | 0.67 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1KDM4EMAPT | |
| SCHEMBL24971012 | 0.67 | DRD4 (0.51) | DRD4DRD3L3MBTL1GAAPDE3B | |
| SCHEMBL856477 | 0.67 | EGFR (0.39) | DRD4DRD3L3MBTL1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| EP-2023728-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | claimed |
| EP-1954137-A4 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-17 | — | — | EP | claimed |
| EP-1954137-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-13 | — | — | EP | claimed |
| WO-2007140005-A2 | OXAZOLYL PIPERIDINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | WO | claimed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | claimed |
| US-9822099-B2 | Triazole derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| EP-2984080-B1 | NOVEL TRIAZOLINTHIONE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2984081-B1 | NOVEL TRIAZOLE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-9550752-B2 | Triazolinthione derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160068516-A1 | NOVEL TRIAZOLE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-03-10 | — | — | US | disclosed |
| US-20160031851-A1 | NOVEL TRIAZOLINTHIONE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| EP-1954137-A4 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1954137-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061862-A2 | 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292266-A1 | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, APEH | DRD4 1350/4885DRD3 864/4885L3MBTL1 4202/4885 |
| US-20160068516-A1 | NOVEL TRIAZOLE DERIVATIVES | ERG28, CYP51A1, SBK3 | DRD4 799/4885DRD3 358/4885L3MBTL1 1572/4885 |
| US-20160031851-A1 | NOVEL TRIAZOLINTHIONE DERIVATIVES | CBS, PRDX3, CTH | DRD4 309/4885DRD3 784/4885L3MBTL1 731/4885 |
| US-20090111778-A1 | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase | FAAH, FAAH2, HCRTR2 | DRD4 3361/4885DRD3 2531/4885L3MBTL1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.